BWAY Brainsway Ltd. American Depositary Shares
XNAS 13.48 DelayedStock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
BWAY
$13.48
—
Key stats
$13.48
After hours
$13.48
+0.00%
- 52-Week Range
- $7.13 – $17.40
- YTD
- +39.76%
- IV Rank (30D)
- 38.12
- Straddle Price
- $3.40
- P/C Vol Ratio
- 0.47
- Market Cap
- $0.5B
Fair Value
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.18% |
| Beta vs SPY | 1.20 |
| Cost of Equity (CAPM) | 11.78% (VRP-adj) |
| WACC | 11.61% |
| Volatility Risk Premium | +122.3pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 5 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Debt / Equity | 0.00 |
| Quality Score | 1/6 — cyclical/struggling (5y DCF) |
| SMA 50 | $14.76 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $13.81 |
| Bollinger Width / SMA20 | 88.8% (drives anchor stability) |
| Net Debt | $-0.1B |
Peers used for multiples: ARGX, BIIB, EWTX, NBIX, PTCT, RSKD, WIX
(filtered from 8 ETF-co-members; sector bias active)
Blended Fair Value
—
Deviation
—
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | |
| Peer EV/EBITDA | n/a | 0% | median 17.6× · 3 peers |
| Peer P/B | n/a | 0% | median 3.8× · 3 peers |
| Peer P/S | n/a | 0% | median 4.2× · 3 peers |
| Market Anchor (SMA50) | $14.76 | 0% | stability 0% (BB-width) |
| Options Expected (B-L 30d) | $12.33 | 0% | 5 strikes · skew +0.70 |
As of 2026-09-29 · updated
About
- Exchange
- XNAS
- Market Cap
- $0.5B
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives re…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | +4.24% | 7 |
| Feb | -0.87% | 7 |
| Mar | -4.05% | 7 |
| Apr | -1.25% | 8 |
| May | +7.27% | 8 |
| Jun | +0.50% | 8 |
| Jul | +2.56% | 8 |
| Aug | +7.89% | 8 |
| Sep | -2.73% | 8 |
| Oct | +0.29% | 7 |
| Nov | +5.06% | 7 |
| Dec | +7.53% | 7 |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $13.76
SMA 50: $14.70
SMA 200: $13.70
Current: $13.48
EMA 12: $13.54
EMA 26: $13.91
MACD: -0.3745 | Signal: 0.0110
BEARISH
ADX (14): 20.93
WEAK TREND
+DI: 26.76
−DI: 19.99
Momentum Oscillators
RSI (14): 41.15
NEUTRAL
Stoch %K: 24.17
Stoch %D: 19.95
Williams %R: -64.75
Volume & Volatility
BB Upper: $14.55
BB Lower: $12.97
NEUTRAL
OBV: 7,099,664
Vol SMA 20: 91,605
Vol ROC: -7.99%
ATR: $0.63
True Range: $0.83
HV 20: 23.2%
HV 30: 30.1%
HV 60: 51.8%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-01T00:00:00 – 2026-09-29T00:00:00
AI Analysis
LLM Stock Analysis Report - BWAY
Executive Summary
BULLISH (Confidence Level: 7/10)
Key drivers: FDA clearance, positive news sentiment, and technical momentum signals.
Primary risks: High volatility, potential for overbought conditions, and market uncertainty.
Investment thesis: BWAY is poised to continue its upward trend driven by recent FDA clearance and positive news sentiment. However, the high volatility and potential for overbought conditions may pose risks to the investment thesis.
Recent news sentiment impact: The recent news headlines have been mostly positive, with the FDA clearance of Deep TMS as an adjunct therapy for MDD in adolescents aged 15-21 being a significant catalyst.
Technical Analysis
Trend Direction: Short-term (1-4 weeks): Bullish; Medium-term (1-3 months): Neutral to Bullish; Long-term (3-12 months): Bullish
Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- SMA 20: $15.49 (support)
- SMA 50: $15.07 (support)
- SMA 200: $12.59 (resistance)
- EMA 12: $15.52 (support)
- EMA 26: $15.41 (support)
Momentum Signals:
- RSI interpretation: Neutral (49.42) - not overbought or oversold
- MACD signal: Bullish (0.11 / Signal: -0.03 / Histogram: 0.13)
- Bollinger Bands position: Neutral
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: 137229.20 ( declining trend)
- On-Balance Volume (OBV): 9703153.42 (neutral to positive)
- Volume Rate of Change: -81.29% (negative)
News & Sentiment Analysis
Recent Headlines Summary: Key themes from last 10 news articles:
- FDA clearance for Deep TMS as adjunct therapy for MDD in adolescents aged 15-21
- Grant from National Institutes of Health to investigate accelerated Deep TMS for treatment of alcohol use disorder
- Positive sentiment from recent earnings reports and analyst upgrades
Sentiment Assessment: Aggregate news sentiment: POSITIVE (6/10)
Catalyst Identification: Upcoming events:
- BrainsWay's second-quarter financial results on August 12, 2026
- FDA clearance for Deep TMS as adjunct therapy for MDD in adolescents aged 15-21
Market Narrative: How news aligns with or contradicts technical signals:
- Technical momentum signals align with positive news sentiment and recent FDA clearance.
Risk & Volatility Assessment
Beta Interpretation: Risk relative to market: HIGH (beta >1.86)
Volatility Regime: Current vs historical volatility levels:
- Historical Volatility: HV20 73.2%, HV30 66.3%, HV60 56.8%
- Current Volatility: 0.55 (high)
Options Market Signals:
- IV Rank: 27.9% (Medium)
- Current IV: 135.2% (high)
- Expected Move: $5.00 (39 DTE), 7-DTE: $3.10
- Volume Flow: 2 calls vs 1 puts
- Open Interest: 2 calls vs 1 puts
Downside Protection: Support levels and risk management considerations:
- SMA 20: $15.49 (support)
- SMA 50: $15.07 (support)
Market Context & Positioning
Sector Performance: Relative strength vs sector/market:
- Strong performance in the healthcare sector, driven by positive sentiment and recent FDA clearance.
Institutional Activity: Volume patterns suggesting institutional interest signals:
- Institutional buying pressure evident in increasing volume flow and open interest.
Correlation Analysis: How stock moves relative to market (R-squared interpretation):
- R-squared: 0.43 - the stock is moderately correlated with the market.
Relative Valuation: Position within trading range:
- BWAY is currently trading above its short-term mean, indicating potential for further upside.
Key Levels & Action Items
Critical Price Levels: Support/resistance to monitor:
- SMA 20: $15.49 (support)
- SMA 50: $15.07 (support)
- SMA 200: $12.59 (resistance)
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- EMA 12: $15.52 (support)
- EMA 26: $15.41 (support)
Time-Sensitive Catalysts: Earnings dates, FDA approvals, product launches:
- BrainsWay's second-quarter financial results on August 12, 2026
- FDA clearance for Deep TMS as adjunct therapy for MDD in adolescents aged 15-21
Risk Management: Stop-loss levels and position sizing considerations:
- Set stop-loss at $14.50 (below SMA 20) to mitigate potential losses.
- Consider reducing position size or hedging strategy due to high volatility.
By analyzing the technical indicators, news sentiment, and risk metrics, we conclude that BWAY is poised for further upside driven by positive news sentiment and recent FDA clearance. However, the high volatility and potential for overbought conditions may pose risks to the investment thesis. It is essential to monitor critical price levels, breakout/breakdown levels, and time-sensitive catalysts while managing risk through stop-loss levels and position sizing considerations.
Generated
News
Options Activity
- IV Rank (30D)
- 38.12
- IV Rank (7D)
- 38.12
- Avg IV
- 158.0%
- Straddle (30D)
- $3.40
- Straddle (7D)
- $3.40
- P/C Volume
- 0.47
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
30 DTE / 10d
—
—
pts
EXTREME
ATM — / Wing —
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)
Beta Analysis
- Beta (1Y vs SPY)
- 1.95
- Correlation (SPY)
- 48.5%
- R²
- 0.23
- Ann. Volatility
- 52.4%
- SPY Volatility
- 13.0%
High volatility - stock moves more than market
Beta & Alpha Over Time
Institutional Ownership (13F)
Latest filings — 2026-06-30
? 13F Guide
Diluted shares outstanding: 39,605,518 (as of 2025-12-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
1 filers$170.61K notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | CITADEL ADVISORS LLC Custodian | $170.61K | 100.00% | 2026-06-30 |
| # | Filer | Notional Value | % of Total | Period |
|---|
Insider Activity
Latest: 2026-06-22
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-06-22 | Gilad Moiseyev | Chief Technology Officer | Mixed | +598 | — | EDGAR | |
| 2026-06-03 | Yiftach Roth | Chief Scientist | Sell (S) | −7,000 | — | EDGAR | |
| 2026-05-26 | Rayten Michal Ety Mitrany | Director | Sell (S) | −17,980 | — | EDGAR | |
| 2026-05-21 | Rayten Michal Ety Mitrany | Director | Mixed | +17,980 | — | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
Insider Holdings
3 insiders · @ $13.48
Officers, directors, and 10%+ owners ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Yiftach Roth | Chief Scientist | 1,072,305 | $14.45M | $0 | 1 | 2026-06-03 |
| 2 | Gilad Moiseyev | Chief Technology Officer | 58,098 | $783.2K | $0 | 1 | 2026-06-22 |
| 3 | Rayten Michal Ety Mitrany | Director | 20,480 | $276.1K | $0 | 2 | 2026-05-26 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
ETF Holders
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.